Key result
Obesity linked to ~3-fold greater risk of incident CVD one year after COVID-19 pneumonia.
Why the study?
To evaluate clinical and echocardiographic parameter changes over one year following COVID-19 pneumonia in individuals without cardiovascular disease, based on the presence of obesity.
Does obesity worsen clinical and echocardiographic parameters in patients without prior cardiovascular diseases within a year after COVID-19 pneumonia?
Cohort (n=73)
Does obesity worsen clinical and echocardiographic parameters in patients without prior cardiovascular diseases within a year after COVID-19 pneumonia?
Absolute Event Rate: 55% vs 17%
Obesity is associated with a higher incidence of newly developed cardiovascular diseases and worse left ventricular systolic and diastolic function one year after COVID-19 pneumonia in patients without prior CVD.
Should not yet change post-COVID surveillance; hypothesis-generating for obesity as modifiable CVD risk factor.
Aim. To study the changes of clinical and echocardiographic parameters in people without cardiovascular diseases (CVDs) within a year after coronavirus disease 2019 (COVID-19) depending on the obesity presence. Material and methods. During the year after COVID-19 pneumonia, the clinical and echocardiographic parameters of 21 patients with obesity and without CVD were compared. The group both without CVDs and obesity consisted of 52 patients comparable by sex and age. Results. Newly developed CVDs were registered in 55% and 17% of the group with and without obesity, respectively. Left ventricular (LV) global longitudinal strain 3 months (-18,4±2,3 vs -20,6±2,2%, p=0,010) and one year after COVID-19 pneumonia (-18,8±1,8 vs -20,8±2,5%, p=0,021) was lower in the group with obesity. Lateral (e' later) (10,8±3,3 vs 13,1±2,9 cm/s (p=0,007)) and septal (e' sept) (8,5±2,7 vs 10,1±2,0 cm/s (p=0,011)) early diastolic mitral annulus velocity, as well as the ratio of early and late diastolic LV filling (E/A) (1,1±0,3 vs 1,2±0,3 (p=0,019)) at the end of the follow-up were lower in the group with obesity. Conclusion. In people without CVDs during a year after COVID-19 pneumonia, a high prevalence of newly developed CVD was noted in 55% and in 17% of people with and without obesity, which was accompanied by worse LV systolic and diastolic function in the group with obesity.
No takes yet. Share an insight, caveat, or question.
Yaroslavskaya et al. (2023) conducted a cohort in COVID-19 pneumonia without prior cardiovascular diseases (n=73). Obesity vs. Without obesity was evaluated on Newly developed cardiovascular diseases. Obesity in patients without prior cardiovascular disease was associated with a higher rate of newly developed cardiovascular diseases at one year after COVID-19 pneumonia (55% vs 17%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: